Dr. Reddy's founder dies; Par to make generic Luvox CR; Teva to pay pollution penalty;

@FiercePharma: Claris injectables unit seen as M&A target for Teva, Pfizer, now that Mylan has Agila Specialties. More | Follow @FiercePharma

@EricPFierce: FDA acts quickly to assess potential cancer risks of type 2 diabetes drugs, Merck's Januvia, BMS' Byetta. Story | Follow @EricPFierce

> Teva Pharmaceutical ($TEVA) will pay $2.25 million to settle alleged environmental violations over a plant in Mexico, MO. Report

> Kallam Anji Reddy, 73,  founder and chairman of Dr Reddy's Laboratories, died Friday in India after brief illness. Item

> Some members of Congress are displeased with an FDA response as to how long it could take to put greater restrictions on prescription painkillers like Vicodin. Story 

> The FDA has officially withdrawn Impax Laboratories' bupropion hydrochloride which the agency asked last fall to be taken off the market over concerns of its bioequivalence. Report

> The FDA has given Par Pharmaceutical the go-ahead to make a generic version of Jazz Pharmaceuticals' Luvox CR. Item 

Medical Device News

 @FierceMedDev: Intuitive slides as doc group slams robotic surgery 'hype. More | Follow @FierceMedDev

 @MarkHFierce: A brain Dx would measure tumor DNA to gauge how advanced breast cancer patients are responding to drugs. Article | Follow @MarkHFierce

 @DamianFierce: Illumina has to fork over $96 million in a patent suit over sequencing. Story | Follow @DamianFierce

> Sorin banks on up to 30% profit growth in 2013. More

> Study: Johns Hopkins brain stent saves patients from blindness. Article

Biotech News

 @FierceBiotech: Novartis grabs FDA's coveted 'breakthrough' status for lung cancer drug. More | Follow @FierceBiotech

@JohnCFierce: Tillman Gerngross (Adimab) has a new biotech startup, Avitide. A service company: More | Follow @JohnCFierce

@RyanMFierce: Merck hit with delay on FDA review of top drug prospect. Article | Follow @RyanMFierce

> Biotech startup Avitide attracts venture funding from familiar VC crowd. More

> Biotech Chimerix reveals ex-Pharmasset recruit after unveiling $85M IPO plan. Report

And Finally... In a long but not very insightful interview, former Novartis ($NVS) Chairman Daniel Vasella talks about his fight over an abandoned $76 million payout and his decision to move to the U.S. Story 

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.